Revolution Medicines · 17 hours ago
Intern, NDCP (Undergraduate)
San Francisco Bay Area
Internship
Onsite
Intern
$67K/yr - $81K/yrRevolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers. They are seeking a highly motivated Clinical Pharmacology Summer Intern to support ongoing clinical development programs, where the intern will work closely with clinical pharmacologists and contribute to PK/PD analysis and clinical strategy.
Health CareLife ScienceMedical
Responsibilities
Assist in the analysis and interpretation of clinical PK/PD data
Support noncompartmental and/or model-based analyses
Contribute to study protocol, clinical study report, and internal presentations
Attend team meetings/scientific discussions related to drug development
Qualification
Required
Currently pursuing a Bachelor's degree in Biomedical Engineering, System Biology, or related field
Curiosity and eagerness to learn about drug development
Strong analytical and quantitative skills
Good time management and organizational skills
Ability to work independently and in a team environment
Strong written and verbal communication skills
Preferred
Experience with data visualization and reporting
Familiarity with tools such as R, WinNonlin or similar modeling software
Benefits
Competitive cash compensation
Robust equity awards
Strong benefits
Significant learning and development opportunities
Company
Revolution Medicines
Revolution Medicines is an innovative and dynamic organization of expert biologists, chemists, pharmacologists, clinical scientists.
Founded in 2015
501-1000 employees
H1B Sponsorship
Revolution Medicines has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (13)
2024 (18)
2023 (15)
2022 (8)
2021 (1)
2020 (2)
Funding
Current Stage
Public CompanyTotal Funding
$2.25BKey Investors
Royalty PharmaBoxer CapitalNextech Invest
2025-06-24Post Ipo Debt· $250M
2024-12-02Post Ipo Equity· $750M
2023-03-02Post Ipo Equity· $323.6M
Leadership Team
Luan Wilfong
Chief Human Resources Officer
Steve Kelsey
President
Recent News
Genetic Engineering News
2026-02-02
Pharmaceutical Technology
2026-01-13
Company data provided by crunchbase